Reading this on a mobile device? Try our optimized mobile version here:

January 11, 2013News for medical technology professionals

  Top Story 
  • FDA widens clearance for Siesta's tongue suspension device
    The FDA has given Siesta Medical expanded clearance for the company's Encore tongue suspension device. The company, which is headquartered in Los Gatos, Calif., can now market the device for multiple suspension loop applications and as a fully adjustable system after implantation in patients with obstructive sleep apnea. "Siesta believes the Encore system is a ... cost effective surgical option for treating OSA patients unable to comply with CPAP use,” said company President and CEO Peter Martin. (1/9) LinkedInFacebookTwitterEmail this Story
  Business & Market Trends 
  • Minn. wrist fracture device startup hopes to raise $2 million
    A regulatory filing disclosed that Conventus Orthopaedics is looking to obtain $2 million in a funding round. The Minnesota-based startup has developed the Distal Radius Surgical System, an implantable device that directs treatment to distal radius fractures while leaving the area surrounding the wrist untouched. (1/10) LinkedInFacebookTwitterEmail this Story
  • Ohio startup gets $250K boost for coronary artery guide wire
    JumpStart, a nonprofit development group, has invested $250,000 in Guided Interventions. The Cleveland startup will use the funding to develop a prototype of a guide wire that uses fractional flow reserve, a method that measures variations in pressure levels across a coronary artery stenosis, to treat patients with the condition. (1/9) LinkedInFacebookTwitterEmail this Story
  International Developments 
  • Report predicts growth for European molecular imaging markets
    European molecular imaging markets reached $276 million in 2011 and could produce revenues of $388 million in 2018, according to a report from Frost & Sullivan. The report predicts that Italy, Scandinavia and the Benelux region (Belgium, the Netherlands and Luxembourg) will show the earliest growth, followed by France and Spain. Growth will be driven by the increasing adoption of molecular imaging in neurology and the development of advanced modalities such as PET/MR, the report said. (1/9) LinkedInFacebookTwitterEmail this Story
  Science & Health 
  Emerging Technologies 
  • Artificial disc device from AxioMed nears trial completion
    AxioMed Spine expects to complete a pivotal U.S. study of its Freedom Lumbar Disc, which is used to treat patients suffering from degenerative spine disease, before the end of the quarter. The Cleveland company, which has secured $3.6 million in its latest funding round, will use data from the trial to back its FDA clearance application for the device. (1/10) LinkedInFacebookTwitterEmail this Story
  Government & Regulatory 
  • FDA clears cough therapy device from Philips Respironics
    The FDA has given Philips Respironics 510(k) clearance to market its CoughAssist T70 system, which is intended to provide an alternative to manual airway suctioning in patients who have difficulty coughing. The device works by generating a cough-like movement through the airway and gathers the phlegm that is discharged. (1/8) LinkedInFacebookTwitterEmail this Story
AdvaMed News 
  • Medical Device Reimbursement Workshop
    Tuesday, Feb. 26 – Wednesday, Feb. 27
    Sheraton Crystal City, Arlington, Va.
    AdvaMed MTLI’s workshop for medical technology reimbursement professionals will provide the road map to successfully navigate the many potential pitfalls. After an overview of reimbursement issues, the workshop will drill down to coding systems, technology assessments and differences in inpatient and outpatient payment systems. Hear from experts on how to negotiate CMS coverage. Learn how to plan for the new health care reform landscape, deal with comparative effectiveness and manage international reimbursement. Visit MTLI online for more information. LinkedInFacebookTwitterEmail this Story
  • Follow AdvaMed on Google+
    Stay updated on industry news and educational opportunities -– receive an intimate understanding of the key issues affecting innovation, access and the bottom line. Network with industry experts and leaders. Our Google+ page is interactive and incorporates updates from key stakeholders, influencers and industry thought leaders as well as regulatory and policy experts from the FDA and CMS. Follow us on Google+. LinkedInFacebookTwitterEmail this Story
Learn more about AdvaMed ->About AdvaMed | Join | Courses | Events | Newsroom

Position TitleCompany NameLocation
IP Litigation Counsel - 001980Edwards LifesciencesIrvine, CA
Quality Systems ManagerRoche DiagnosticsIndianapolis, IN
Regulatory Affairs Clinical SpecialistMindray DS USA, Inc.Mahwah, NJ
Area Reimbursement Manager (Central U.S. or Northeast U.S.)SI-BONE, IncMultiple Locations, United States
Program Director, Regulatory AffairsJohnson & JohnsonFremont, CA
Click here to view more job listings.

The most valuable of all talents is that of never using two words when one will do."
--Thomas Jefferson,
3rd U.S. president

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Account Director:  Meryl Harold (202) 407-7828
Job Board:  Jackie Basso (202) 407-7871
A powerful website for SmartBrief readers including:
 Recent AdvaMed SmartBrief Issues:   Lead Editor:  Lisa Gough
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2013 SmartBrief, Inc.® Legal Information